Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
IBIO - iBio, Inc.
$1.47
-0.14(-8.70%)9:00:00 PM 11/23/2020
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    11/16/2020IBIO
    iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update

    BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30, 2020. “We made tremendous strides during the first few months of Fiscal Year 2021 in executing our strategy to transform iBio from a modestly performing contract manufacturer into a dynamic, diversified, innovative biotechnology company,” said Tom ...

    11/15/2020IBIO
    3 Ultra-Risky Robinhood Stocks That Just Might Make You a Fortune

    In August, iBio (NYSEMKT: IBIO) announced encouraging preclinical results for experimental COVID-19 vaccine IBIO-201. In addition, iBio licensed a COVID-19 therapeutic candidate, ACE2-Fc, from Planet Biotechnology. If the company's COVID-19 vaccine and/or its therapeutic candidate go on to deliver great results in clinical testing, though, the biotech stock could soar a lot higher than its year-to-date gain of more than 580%.

    11/13/2020IBIO
    Up 600% Year-to-Date, Sell iBio Stock While It’s Still Flying High

    It’s been an incredible comeback year for iBio (NYSEAMERICAN:IBIO). Up until 2020, IBIO stock had a long and unfortunate run as a publicly traded investment. Shares dropped from a peak of $55 each in 2011 to as low as 5 cents last year. However, for the fledgling biotech and vaccine company, the novel coronavirus gave it a new lease on life. Here’s the latest in iBio news. Source: Maksim Shmeljov / Shutterstock.com Shares roared from that 5-cent low to as high as $7 this year. That came as iBi...

    11/12/2020IBIO
    iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium

    BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) --  iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners’ Virtual Healthcare Symposium on November 19, 2020. In addition to participating in a series of one-on-one meetings with institutional investors throughout the day, iBio will participate on a panel hosted by Jim Molloy, Alliance Global Partners’ Manag...

    11/5/2020IBIO
    iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020

    BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results after market close on Monday, November 16, 2020. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Compan...

    11/3/2020IBIO
    iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

    \- Brings >20 Years of Global Biotech Operations and Business Development Experience -BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (“COO”), effective December 1, 2020. Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business development and relations...